Experimental Therapeutics Program

实验治疗学（ET）计划提供了一个有组织的综合基础设施， 西蒙斯综合癌症中心基础和人口科学研究的临床翻译 （SCCC）研究计划和临床相关假设的识别，以供SCCC基础科学测试 程序.四个项目的具体目标集中在治疗开发和生物标志物发现，其中 成员们共同努力：（1）开发分子治疗增敏剂， 增强现有疗法的独特肿瘤选择剂，（2）靶向肿瘤微环境， 通过调节免疫细胞在肿瘤进展中的作用进行免疫治疗，（3）先进的成像和药物 通过开发新的成像和纳米技术交付平台，以提高癌症诊断和 （4）通过利用合成致命性作为新的“靶向”治疗， 癌ET计划汇集了来自6个基础科学和12个临床部门的78名SCCC成员 包括44个国家癌症研究所资助的项目，包括两个SPORE和14个多PD/PI奖。针对评价 活动和战略目标，以促进合作转化研究，ET招募了新的高级临床 研究人员;扩大转化研究和药物启动的临床试验（IIT），以包括大多数癌症 类型，并满足集水区的需求;加强与SCCC成员的互动;综合 放射肿瘤学教师加入该计划;并改善了IIT的基础设施和资金。ET成员 参与并领导多中心IIT，他们与制药/生物技术合作，这通常会导致 制药商发起的试验和转化研究。重要的是，在肾脏和肺的资助孢子计划， 癌症和新的SPORE应用在前列腺癌和肝癌的积极支持ET成员 专业知识ET计划扩大了大多数成人和儿童癌症的治疗渠道。 突出的成功包括治疗策略的内部开发和临床翻译， KRAS突变型癌症，针对肾癌的HIF 2 α靶向，针对突变型雌激素受体的拮抗剂， 乳腺癌，激活STING先天免疫途径的策略，以及利用 立体定向放射治疗和免疫检查点抑制剂之间的协同作用。未来的方向包括 投资于临床前模型（球状体/类器官培养物、人源化小鼠）、精密肿瘤学（定制 小组，SCCC分子肿瘤委员会，基因组肿瘤学翻译领导者的招募），免疫- 肿瘤学（免疫分析;新型PET示踪剂;全身和器官特异性自身抗体生物标志物;扩展 先天免疫计划），以疾病为重点的转化研究计划（招聘领导， 乳腺、GI、肺、GU、神经肿瘤、血液恶性肿瘤和I期项目）;以及 与社区外展，教育和公平办公室的互动，以增加临床试验应计费用 在我们的集水区和服务不足的地区。

The Experimental Therapeutics (ET) Program provides an organized integrated infrastructure that enables both clinical translation of basic and population science research from Simmons Comprehensive Cancer Center (SCCC) research programs and identification of clinically relevant hypotheses for testing by SCCC basic science programs. The four program specific aims focus on therapeutic development and biomarker discovery, where members work collectively to: (1) develop molecular therapeutic sensitizers by focusing on the development of unique tumor-selective agents that enhance existing therapies, (2) target tumor microenvironment with immunotherapy by modulating the role of immune cells in tumor progression, (3) advance imaging and drug delivery by developing novel imaging and nanotechnology delivery platforms to enhance cancer diagnosis and therapy, and (4) exploit cancer vulnerabilities by leveraging synthetic lethalities as new “targeted” therapy for cancer. The ET Program brings together 78 SCCC members from six basic science and 12 clinical departments comprising 44 NCI-funded projects, including two SPOREs and 14 multi-PD/PI awards. In response to evaluative activities and strategic goals to facilitate collaborative translational research, ET recruited new senior clinical researchers; expanded translational studies and investigator-initiated clinical trials (IITs) to include most cancer types and to address the needs of the catchment area; enhanced interactions with SCCC members; integrated radiation oncology faculty into the program; and improved the infrastructure and funding for IITs. ET members participate in and lead multicenter IITs and they collaborate with pharma/biotech, which often leads to investigator-initiated trials and translational studies. Importantly, the funded SPORE programs in kidney and lung cancers and new SPORE applications in prostate and liver cancers are actively supported by ET member expertise. The ET Program has expanded therapeutic pipelines in a majority of adult and pediatric cancers. Highlighted successes include the in-house development and clinical translation of therapeutic strategies for KRAS mutant cancers, HIF2alpha-targeting for kidney cancer, antagonists against mutant estrogen receptors in breast cancers, strategies to activate the STING innate immune pathway, and clinical trials capitalizing on synergy between stereotactic radiation therapy and immune checkpoint inhibitors. Future directions include investment in preclinical models (spheroid/organoid cultures, humanized mice), precision oncology (customized panels, SCCC molecular tumor boards, recruitment of a translational leader in genomic oncology), immuno- oncology (immune profiling; novel PET tracers; systemic and organ-specific autoantibody biomarkers; expansion of the innate immunity program), disease-focused translational research programs (recruitment of leadership in breast, GI, lung, GU, neuro-oncology, hematologic malignancies, and Phase I programs); and expansion of interactions with the Office of Community Outreach, Education & Equity in order to increase clinical trial accruals across our catchment area and among the underserved.